ClinConnect ClinConnect Logo
Search / Trial NCT05639400

Thoraflex Hybrid and Relay Extension Post-Approval Study

Launched by VASCUTEK LTD. · Dec 5, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Tevar Frozen Elephant Trunk (Fet)

ClinConnect Summary

The Thoraflex Hybrid and Relay Extension Post-Approval Study is looking at how effective a medical device called the Thoraflex Hybrid is in treating certain serious conditions that affect the aorta, which is the main artery in the body. This study will also explore how well the Thoraflex Hybrid works when used together with another device called the RelayPro NBS stent-graft. Patients who are 18 years or older and are being treated with the Thoraflex Hybrid device, with the possibility of additional treatment using the RelayPro device, may be eligible to join the study.

If you participate, you can expect to have your treatment monitored over a period of 10 years, following standard medical care at the hospital where you receive treatment. To join, you need to give your consent and be able to attend regular check-ups. However, if you have certain medical or psychological conditions that may affect your ability to participate safely, you may not qualify for the study. This research aims to gather important information to help improve treatments for aortic diseases, benefiting future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient is aged 18 years or older on date of consent. Patient is willing and able to comply with all study procedures and visits. Patient or their next of kin (NOK)/legally designated representative (LDR) has given written informed consent to participate in the study.
  • Patient will undergo treatment with a Thoraflex Hybrid device. If a patient requires an extension procedure due to the extent of aortic disease, a RelayPro NBS Stent-graft should be placed inside the distal end of the previously placed Thoraflex Hybrid device via a retrograde approach. This may be part of the same or a two-stage procedure.
  • Exclusion Criteria:
  • Patient has any medical, social, or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure.

About Vascutek Ltd.

Vascutek Ltd. is a leading medical device company specializing in the development and manufacturing of innovative vascular grafts and associated technologies. With a commitment to advancing patient care, Vascutek is dedicated to providing high-quality, reliable solutions for the treatment of vascular diseases. The company's extensive expertise in biomaterials and surgical techniques underpins its clinical trials aimed at evaluating the safety and efficacy of its products. Vascutek's mission is to enhance surgical outcomes and improve the quality of life for patients worldwide through rigorous research, collaboration, and adherence to the highest standards of regulatory compliance.

Locations

Chicago, Illinois, United States

Boston, Massachusetts, United States

Philadelphia, Pennsylvania, United States

Baltimore, Maryland, United States

Salt Lake City, Utah, United States

St. Louis, Missouri, United States

Aurora, Colorado, United States

Saint Louis, Missouri, United States

Hartford, Connecticut, United States

Durham, North Carolina, United States

Barcelona, , Spain

Pittsburgh, Pennsylvania, United States

Salzburg, , Austria

Freiburg, , Germany

New York, New York, United States

New York, New York, United States

Toulouse, , France

Saint Herblain, , France

Los Angeles, California, United States

Los Angeles, California, United States

Washington, District Of Columbia, United States

Houston, Texas, United States

Birmingham, Alabama, United States

Indianapolis, Indiana, United States

Austin, Texas, United States

Bologna, , Italy

Oxford, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Martin Czerny

Principal Investigator

University of Freiburg

Joseph E Bavaria

Principal Investigator

Jefferson Health and Sidney Kimmel Medical College

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials